Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Disc Medicine is a biopharmaceutical company that develops therapies for hematologic diseases and rare blood disorders.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.
ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
TriGemX Bio uses the science of gut-brain biology to create medicines that transform human health.
AN2 Therapeutics develops small-molecule medicines from boron chemistry for infectious diseases, hematologic disorders, and oncology.
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
Vaderis Therapeutics is a clinical-stage biotechnology company developing targeted therapies for rare vascular diseases.
LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.
Ollin Biosciences develops ophthalmic therapies focused on treating serious vision-threatening diseases.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
Abivax develops medicines that alter the body's natural immune system mechanisms.
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.
Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.
Perspective Therapeutics focuses on advancing cancer treatments employing radiation, radiopharmaceuticals, and imaging technology.
Century Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.
Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.
TCG Crossover has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
TCG Crossover's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Pharmaceutical. The firm invests across 10 different industry categories.
Among tracked funding rounds, Mirum Pharmaceuticals received $600.0M in a Post-IPO Debt round. TCG Crossover's total known invested capital is $14.3B.
TCG Crossover's average investment size is $176.4M across its portfolio of 81 companies.
Recent TCG Crossover portfolio additions include Aclaris Therapeutics, Disc Medicine, Alector, Soufflé Therapeutics, ADC Therapeutics. These companies were founded in 2020 or later.